Healthcare Standards for Children and Young People in Secure Settings – Royal College of Paediatrics and Child Health

There are about 1,000 children and young people held in secure settings at any one time. They are some of the most vulnerable, often suffering poor physical and mental health. These standards – first published in 2013, and refreshed in

Updated guidelines on post exposure prophylaxis (PEP) for varicella/shingles – Public Health England

Guidance on the use and ordering of varicella zoster immunoglobulin (VZIG).  Varicella zoster immunoglobulin (VZIG) is a scarce blood product that is offered to individuals at high risk of severe chickenpox following an exposure. Post exposure prophylaxis (PEP) is offered to

Guidelines on Post-Exposure Prophylaxis for measles – Public Health England

This guidance summarises the evidence for the effectiveness of post-exposure prophylaxis (PEP) for measles and provides advice on the assessment for PEP for high risk groups, in the following order of priority: immunosuppressed individuals pregnant women and infants

Guidance on the High Security Psychiatric Services (Arrangements for Safety and Security) Directions 2019 – Department of Health and Social Care

Guidance on directions on safety and security to providers of high security psychiatric services. The directions apply to providers of high security psychiatric services. They set out the requirements for providers to make sure they have robust arrangements for safety

Guidance: High security psychiatric services directions 2013: arrangements for visits by children – Department of Health and Social Care

The directions apply to providers of high security psychiatric services. They set out the requirements for providers when arranging visits by children to patients in high security hospitals.

Frequently asked questions on Data Protection in a no deal EU Exit – NHS England

If the UK leaves the EU without a deal, there will be no immediate change in the UK’s own data protection standards. The UK would continue to allow the free flow of personal data from the UK to the European

NHS Property: Guidance for NHS Trusts and Foundation Trusts on requesting transfers of estate in the ownership of NHS property companies – NHS England

Guidance for NHS trusts and foundation trusts on requesting transfers of estate owned by NHS Property Services and Community Health Partnerships.  This guidance sets out: the reasons for allowing trusts to request transfers of properties from property companies that are owned

Test Site Top Tips: Learning from the Faster Diagnosis Standard Test Sites – NHS England

This handbook contains tips from the five Faster Diagnosis Standard (FDS) test sites, who worked collaboratively with NHS England to: Robustly test and develop the rules for the faster diagnosis standard Explore impact on patients and the clinical services of

Clinical Commissioning Policy: 18Ffluorodeoxyglucose (FDG) positron emission tomography-computedtomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages) – NHS England

NHS England will not routinely commission 18F-FDG-PET CT as part of radical radiotherapy treatment planning for oesophageal cancer in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the

Clinical Commissioning Policy: Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages): Consultation Report – NHS England

NHS England will not routinely commission hyperbaric oxygen therapy for diabetic lower limb ulceration in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment.

NHS England: Evidence review: Hyperbaric oxygen therapy for diabetic lower limb ulceration refractory to best standard care – NHS England

NHS England will not routinely commission hyperbaric oxygen therapy for diabetic lower limb ulceration in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment.

Clinical Commissioning Policy: Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages): Clinical Panel Review – NHS England

NHS England will not routinely commission hyperbaric oxygen therapy for diabetic lower limb ulceration in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment.

Clinical Commissioning Policy: Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages) – NHS England

NHS England will not routinely commission hyperbaric oxygen therapy for diabetic lower limb ulceration in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment.

Clinical Commissioning Policy Statement: Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages) [170117P] – NHS England

This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).  

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Clinical Panel Report – NHS England

Clinical Panel report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Clinical Priorities Advisory Group Report – NHS England

Clinical Priorities Advisory Group report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Engagement Report – NHS England

Engagement report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).